JP2014516552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516552A5 JP2014516552A5 JP2014513800A JP2014513800A JP2014516552A5 JP 2014516552 A5 JP2014516552 A5 JP 2014516552A5 JP 2014513800 A JP2014513800 A JP 2014513800A JP 2014513800 A JP2014513800 A JP 2014513800A JP 2014516552 A5 JP2014516552 A5 JP 2014516552A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- cancer
- biomarkers
- biomarker
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492488P | 2011-06-02 | 2011-06-02 | |
| US61/492,488 | 2011-06-02 | ||
| PCT/US2012/040805 WO2012167278A1 (en) | 2011-06-02 | 2012-06-04 | Molecular diagnostic test for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248061A Division JP2017079772A (ja) | 2011-06-02 | 2016-12-21 | 癌の分子的診断検査 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516552A JP2014516552A (ja) | 2014-07-17 |
| JP2014516552A5 true JP2014516552A5 (enExample) | 2016-02-25 |
| JP6067686B2 JP6067686B2 (ja) | 2017-01-25 |
Family
ID=47259970
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513800A Expired - Fee Related JP6067686B2 (ja) | 2011-06-02 | 2012-06-04 | 癌の分子的診断検査 |
| JP2016248061A Withdrawn JP2017079772A (ja) | 2011-06-02 | 2016-12-21 | 癌の分子的診断検査 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248061A Withdrawn JP2017079772A (ja) | 2011-06-02 | 2016-12-21 | 癌の分子的診断検査 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10260097B2 (enExample) |
| EP (1) | EP2715348B1 (enExample) |
| JP (2) | JP6067686B2 (enExample) |
| KR (1) | KR20140044341A (enExample) |
| CN (1) | CN103733065B (enExample) |
| AU (1) | AU2012261820B2 (enExample) |
| BR (1) | BR112013031019A2 (enExample) |
| CA (1) | CA2838086A1 (enExample) |
| EA (2) | EA025926B1 (enExample) |
| IL (1) | IL229681A0 (enExample) |
| MX (1) | MX2013014065A (enExample) |
| SG (2) | SG10201604497UA (enExample) |
| WO (1) | WO2012167278A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| EP2667193A1 (en) * | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| WO2014055398A1 (en) * | 2012-10-05 | 2014-04-10 | Siemens Healthcare Diagnostics Inc. | Method for detecting an increased risk or incidence of colorectal cancer |
| HK1214633A1 (zh) * | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
| GB201313342D0 (en) * | 2013-07-26 | 2013-09-11 | Cancer Rec Tech Ltd | Biomarkers |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| JP2017523776A (ja) * | 2014-07-14 | 2017-08-24 | ジェネンテック， インコーポレイテッド | 膠芽腫の診断方法及びその治療用組成物 |
| WO2016028638A1 (en) * | 2014-08-18 | 2016-02-25 | Drexel University | Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment |
| KR20160101706A (ko) * | 2015-02-17 | 2016-08-25 | 싸이퍼롬, 인코퍼레이티드 | 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법 |
| CN105160208A (zh) * | 2015-05-29 | 2015-12-16 | 杭州奥视图像技术有限公司 | 用于疾病亚型问题的基于网络的聚类方法 |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| US10650325B2 (en) * | 2015-07-31 | 2020-05-12 | Microsoft Technology Licensing, Llc | Deterministic message distribution |
| CA2996426A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| AU2017211247B2 (en) * | 2016-01-25 | 2023-03-09 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
| US20190127805A1 (en) * | 2016-03-15 | 2019-05-02 | Almac Diagnostics Limited | Gene signatures for cancer detection and treatment |
| WO2018124153A1 (ja) | 2016-12-28 | 2018-07-05 | 公益財団法人がん研究会 | 抗ｖｅｇｆｒ－２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット |
| CN107037210A (zh) * | 2017-04-05 | 2017-08-11 | 北京蛋白质组研究中心 | Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用 |
| WO2018213331A1 (en) * | 2017-05-16 | 2018-11-22 | Lankenau Institute For Medical Research | Compositions comprising ligands to rhob protein and the uses thereof |
| CN111033631B (zh) * | 2017-06-13 | 2024-03-12 | 波士顿基因公司 | 用于生成分子功能谱、对其进行可视化和分类的系统和方法 |
| US20180365372A1 (en) * | 2017-06-19 | 2018-12-20 | Jungla Inc. | Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework |
| EP3461916A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| WO2019165366A1 (en) * | 2018-02-23 | 2019-08-29 | Beth Israel Deaconess Medical Center | Drug efficacy evaluations |
| WO2019200410A1 (en) * | 2018-04-13 | 2019-10-17 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| CN112955260A (zh) * | 2018-06-27 | 2021-06-11 | 定量癌症诊断有限责任公司 | 生物样品保持器和处理器 |
| CN109585011A (zh) * | 2018-10-26 | 2019-04-05 | 朱海燕 | 胸痛患者的病症诊断方法及机器可读存储介质 |
| AU2019378779A1 (en) * | 2018-11-14 | 2021-06-03 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| EP4004927A4 (en) * | 2019-07-22 | 2023-08-02 | Mission Bio, Inc. | USING MACHINE LEARNING TO OPTIMIZE ASSAYS FOR UNICELLULAR TARGETED DNA SEQUENCING |
| KR102289533B1 (ko) * | 2019-08-19 | 2021-08-17 | 주식회사 테라젠바이오 | 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램 |
| US11049590B1 (en) | 2020-02-12 | 2021-06-29 | Peptilogics, Inc. | Artificial intelligence engine architecture for generating candidate drugs |
| TW202208355A (zh) * | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CN116322696A (zh) * | 2020-05-04 | 2023-06-23 | 安进公司 | 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法 |
| CN112489800B (zh) * | 2020-12-03 | 2024-05-28 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的预后评估系统及其应用 |
| CN116312814B (zh) * | 2021-12-02 | 2024-09-27 | 复旦大学 | 一种肺腺癌分子分型模型的构建方法、设备、装置以及试剂盒 |
| CN114624441B (zh) * | 2022-03-04 | 2025-07-18 | 中国人民解放军空军军医大学 | 跨膜蛋白43作为胰腺癌肿瘤诊断标志物的应用 |
| CN115902223B (zh) * | 2022-11-15 | 2025-08-26 | 中国人民解放军空军军医大学 | 蛋白生物标志物在胃癌诊断中的应用 |
| CN116863995B (zh) * | 2023-08-29 | 2024-05-14 | 北京大学第一医院 | Alpk2，itga11，esyt1，cdh17在预测药物出血中的应用 |
| CN118393140B (zh) * | 2024-04-24 | 2025-04-11 | 英科众康(厦门)科技有限公司 | 基于适配体/抗体新型夹心式介导的检测技术在泛癌标志物c1qc诊断中的应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| US6946442B2 (en) | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| WO2004005883A2 (en) * | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| US6998234B2 (en) | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| WO2003096981A2 (en) | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2004108896A2 (en) | 2003-06-03 | 2004-12-16 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| BRPI0511088A (pt) * | 2004-05-14 | 2007-12-26 | Monica Nister | identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib |
| AU2005263972A1 (en) * | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
| JP2008518610A (ja) | 2004-11-03 | 2008-06-05 | アルマック ダイアグノスティックス リミテッド | トランスクリプトームマイクロアレイ技法およびそれを使用する方法 |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20080305962A1 (en) * | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US7919261B2 (en) | 2005-12-05 | 2011-04-05 | Merck Sharp & Dohme Corp. | Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers |
| US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| JP2009524438A (ja) | 2006-01-27 | 2009-07-02 | トライパス イメージング インコーポレイテッド | 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物 |
| CA2639070A1 (en) * | 2006-04-13 | 2007-11-01 | Oncomethylime Sciences S.A. | Novel tumour suppressor |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP2074226A2 (en) | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| NZ582941A (en) | 2007-08-13 | 2012-05-25 | Almac Diagnostics Ltd | A 3' -based sequencing approach for microarray manufacture |
| US20090092603A1 (en) | 2007-09-25 | 2009-04-09 | Bamdad Cynthia C | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009061800A2 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| WO2009076229A2 (en) | 2007-12-07 | 2009-06-18 | Oregon Health & Science University | Methods to determine if a subject will respond to a bcr-abl inhibitor |
| US8114593B2 (en) | 2008-03-12 | 2012-02-14 | University Of Medicine And Dentistry Of New Jersey | Cancer biomarker genes and gene products and methods for using the same |
| WO2009149297A1 (en) * | 2008-06-04 | 2009-12-10 | The Arizona Board Regents, On Behalf Of The University Of Arizona | Diffuse large b-cell lymphoma markers and uses therefor |
| ES2552937T3 (es) | 2008-06-06 | 2015-12-03 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Factor de predicción de supervivencia para linfoma difuso de células B grandes |
| CA2730614A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| DK2368118T3 (da) | 2008-12-23 | 2013-11-25 | Merck Patent Gmbh | Biomarkører til inhibitorer med anti-angiogen aktivitet |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| EP2425020A4 (en) | 2009-05-01 | 2016-04-20 | Genomic Health Inc | GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY |
| US7615353B1 (en) | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| KR101557545B1 (ko) | 2009-09-17 | 2015-10-06 | 에프. 호프만-라 로슈 아게 | 암 환자에서 진단 용도를 위한 방법 및 조성물 |
| EP2975399B1 (en) | 2010-09-15 | 2022-05-11 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CA2862835A1 (en) | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| EP2667193A1 (en) | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| HK1214633A1 (zh) | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
-
2012
- 2012-06-04 US US14/123,406 patent/US10260097B2/en not_active Expired - Fee Related
- 2012-06-04 EP EP12793609.4A patent/EP2715348B1/en active Active
- 2012-06-04 WO PCT/US2012/040805 patent/WO2012167278A1/en not_active Ceased
- 2012-06-04 BR BR112013031019A patent/BR112013031019A2/pt not_active IP Right Cessation
- 2012-06-04 SG SG10201604497UA patent/SG10201604497UA/en unknown
- 2012-06-04 SG SG2013088216A patent/SG195208A1/en unknown
- 2012-06-04 EA EA201391805A patent/EA025926B1/ru not_active IP Right Cessation
- 2012-06-04 MX MX2013014065A patent/MX2013014065A/es unknown
- 2012-06-04 AU AU2012261820A patent/AU2012261820B2/en not_active Ceased
- 2012-06-04 KR KR1020137034588A patent/KR20140044341A/ko not_active Ceased
- 2012-06-04 EA EA201691257A patent/EA201691257A1/ru unknown
- 2012-06-04 CA CA2838086A patent/CA2838086A1/en not_active Abandoned
- 2012-06-04 JP JP2014513800A patent/JP6067686B2/ja not_active Expired - Fee Related
- 2012-06-04 CN CN201280037298.2A patent/CN103733065B/zh not_active Expired - Fee Related
-
2013
- 2013-11-28 IL IL229681A patent/IL229681A0/en unknown
-
2016
- 2016-12-21 JP JP2016248061A patent/JP2017079772A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506506A5 (enExample) | ||
| Campbell et al. | Update on malignant pleural mesothelioma | |
| Sharma et al. | Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma | |
| Zer et al. | ALK-rearranged non–small-cell lung cancer is associated with a high rate of venous thromboembolism | |
| JP2015536667A5 (enExample) | ||
| Kim et al. | Circulating IL-33 level is associated with the progression of lung cancer | |
| Malka et al. | Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| BR112016004963A2 (pt) | biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença | |
| JP2015504677A5 (enExample) | ||
| Ahmadi et al. | Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression | |
| Yang et al. | Expression of STIM1 is associated with tumor aggressiveness and poor prognosis in breast cancer | |
| MX2016004557A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| EP2596363A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| MX384423B (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). | |
| Hu et al. | The prognostic nutritional index and tumor pathological characteristics predict the prognosis of elderly patients with early-stage hepatocellular carcinoma after surgery | |
| Xuelei et al. | ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis | |
| BR112015013879A8 (pt) | aparelho, método para produzir um mix de um primeiro tipo de produtos alimentícios e pelo menos um segundo tipo de produtos alimentícios, e programa de computador | |
| Sangar et al. | Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells | |
| HK1246367A1 (zh) | 转移性疾病的基因标记预测 | |
| Alaklabi et al. | Immunotherapy in malignant peritoneal mesothelioma | |
| MX2016009450A (es) | Ensayo novedoso para detectar periostina humana. | |
| JP2016528914A5 (enExample) | ||
| Shimura et al. | C-reactive protein is a potential prognostic factor for metastatic gastric cancer | |
| Soliman et al. | Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer |